en
Scientific article
English

Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls

Published inVaccine, vol. 40, no. 33, p. 4897-4904
Publication date2022-08
Abstract

Many vaccines demonstrate high effectiveness for years. This prospective multicentre study was conducted in Switzerland to assess the long-term persistence of antibodies to the diphtheria/tetanus (dT)-vaccine in adult patients with rheumatic diseases (PRDs). 163 PRDs and 169 controls were included in the study. The median age of all participants was 50 years (range: 18-83 years) and 56% were female. After a median time interval of 16 years after vaccination, the median anti-vaccine antibody concentrations were lower in PRDs than in controls for tetanus (1.68 vs 2.01; p = 0.049) and diphtheria (0.05 vs 0.22; p = 0.002). Based on the currently accepted seroprotection threshold (antibody concentration ≥ 0.1 IU/ml), PRDs had lower proportions of short-term tetanus and diphtheria protection as demonstrated by crude odds ratios (OR) of 0.30 (p = 0.017) and OR: 0.52 (p = 0.004), respectively. After adjusting for 'age' and 'time since last dT vaccination', the strength of associations became weaker; for tetanus, borderline evidence remained for a true difference between PRDs and controls (OR: 0.36 [p = 0.098]), however, not for diphtheria (OR: 0.86 [p = 0.58]). We hypothesize that in the presence of rheumatic diseases and its immunosuppressive treatment, vaccine-specific long-lived plasma cells (LLPCs) may be diminished or competitively displaced by rheumatism-specific LLPCs, a process which may decrease the persistence of vaccine-specific antibodies. Novel studies should be designed by incorporating methodologies allowing to determine the attributable fraction of immunosuppressive/immunomodulatory medications and rheumatic disease itself on long-lasting vaccine-specific antibody persistence, as well as, further study the role of LLPCs.

eng
Keywords
  • Diphtheria
  • Long-term immunogenicity
  • Rheumatism
  • Tetanus
  • Vaccination
  • Vaccine
Citation (ISO format)
MISCHLINGER, Johannes et al. Long-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls. In: Vaccine, 2022, vol. 40, n° 33, p. 4897–4904. doi: 10.1016/j.vaccine.2022.06.013
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0264-410X
8views
0downloads

Technical informations

Creation03/05/2024 3:08:16 PM
First validation05/06/2024 3:13:49 PM
Update time05/06/2024 3:13:49 PM
Status update05/06/2024 3:13:49 PM
Last indexation05/06/2024 3:14:10 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack